BSE filing, NSE: FISCHER. Summary written from the filing by ALFA Finder's alert engine.
Fischer Medical Ventures Ltd: key numbers
- Share price
- ₹25.02
- Market cap
- ₹1,733 Cr
- Revenue (annual)
- ₹308.6 Cr
- Net profit (annual)
- ₹31.02 Cr
- P/E (TTM)
- 58.1×Sector 34.8×
- Promoter holding
- 63.08%+0.93% QoQ
- FII holding
- 6.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fischer Medical Ventures Ltd
All →Fischer Medical Ventures Management Change
Fischer Medical Ventures appointed Mr. Chan Sing En as Independent Director of SG subsidiary FMV Global Innovations, effective 27 Oct 2026. No financial consideration involved.
Fischer Medical Ventures Other Announcement
Fischer Medical Ventures Ltd filed its quarterly shareholding pattern under Regulation 31. This routine disclosure presents the company's current ownership structure.
Fischer Medical Ventures Annual General Meeting
Fischer Medical Ventures Ltd has issued a Postal Ballot Notice seeking shareholder approval for creating security on subsidiary assets and promoter share pledges for proposed NCD issuance.
Fischer Medical Ventures Board Meeting Outcome
Fischer Medical Ventures' board approved a postal ballot notice for RPT consent and borrowing limits, and appointed a scrutinizer. No material transaction or financial figure was decided at this meeting.
Fischer Medical Ventures Annual General Meeting
Fischer Medical Ventures Limited conducted its 33rd Annual General Meeting via video conferencing on September 29, 2026, with the requisite quorum present.
Fischer Medical Ventures Other Announcement
Fischer Medical Ventures' subsidiaries declared dividends totaling ₹26.95 Crore. This update provides financial information regarding subsidiary cash flows to the exchange.
- Value
- ₹26.95 Cr
Other regulatory approval announcements
All →Arihant Capital Markets Regulatory Approval
Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Emmbi Industries Regulatory Approval
SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.
Bliss GVS Pharma Regulatory Approval
Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.
John Cockerill India Regulatory Approval
John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.